EMA Application withdrawn: Ozespa (briakinumab) — Abbott Laboratories Ltd.

View source ↗

Summary

The EMA withdrew the application for Ozespa (briakinumab) by Abbott Laboratories Ltd. for psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Ozespa (briakinumab)

Snippet

Status: Application withdrawn. Therapeutic area: Psoriasis. MAH: Abbott Laboratories Ltd.. Decision date: 31/01/2011